The 4th Annual Conference of the Emirates Society For Rheumatology in partnership with the American College of Rheumatology
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
17
For the First Time in the Region ESR is Joining Hands with the ACR
President of ACR: The 4 th Annual Conference of the
Dr. David I. Daikh Emirates Society For Rheumatology
President of ESR: in partnership with the American
Dr. Waleed AlShehhi College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
COSENTYX SUMMARY OF PRODUCT CHARACTERISTICS1
Cosentyx™ Important note: Before prescribing, consult full prescribing information. Presentation: Secukinumab. Solution for subcutaneous injection in pre filled syringe or pre-filled pen containing 150 mg of secukinumab. Therapeutic indications: Plaque psoriasis Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are
10 / 2017 / PO04 / CSPA / GULF
candidates for systemic therapy. Psoriatic arthritis Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. Ankylosing spondylitis Cosentyx is indicated for the treatment of active
ankylosing spondylitis in adults who have responded inadequately to conventional therapy. Posology and method of administration: Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated. Posology Plaque psoriasis The recommended dose is 300 mg
of secukinumab by subcutaneous injection with initial dosing at Weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at Week 4. Each 300 mg dose is given as two subcutaneous injections of 150 mg. Psoriatic arthritis For patients with concomitant moderate to severe plaque psoriasis or who are anti-TNFα inadequate responders (IR), the recommended
dose is 300 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at Week 4. Each 300 mg dose is given as two subcutaneous injections of 150 mg. For other patients, the recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2 and 3, followed by monthly
maintenance dosing starting at Week 4. Ankylosing spondylitis The recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at Week 4. For all of the above indications, available data suggest that a clinical response is usually achieved within 16 weeks of treatment. Consideration
should be given to discontinuing treatment in patients who have shown no response by 16 weeks of treatment. Some patients with an initial partial response may subsequently improve with continued treatment beyond 16 weeks. Special populations Elderly patients (aged 65 years and over) No dose adjustment is required. Renal impairment / hepatic impairment
Cosentyx has not been studied in these patient populations. No dose recommendations can be made. Paediatric population The safety and efficacy of Cosentyx in children below the age of 18 years have not yet been established. No data are available. Method of administration Cosentyx is to be administered by subcutaneous injection. If possible, areas of the skin
that show psoriasis should be avoided as injection sites. The powder for solution for injection must be reconstituted before use. For instructions on reconstitution of the medicinal product before administration, see section 6.6 and the Instructions for Use in the package leaflet. Contraindications: • Cosentyx is contraindicated in patients who have/had severe
hypersensitivity reactions reaction to the active substance or to any of the excipients. Warnings and precautions: • Infections: Caution in patients with chronic or history of recurrent infection. If a patient develops a serious infection, the patient should be closely monitored and Cosentyx should not be administered until the infection resolves. Anti-tuberculosis
therapy should be considered prior to initiation of Cosentyx in patients with latent tuberculosis. Cosentyx should not be given to patients with active tuberculosis. • Crohn’s disease: Patients with active Crohn’s disease treated with Cosentyx should be followed closely.• Hypersensitivity reactions: Rare cases of anaphylactic reactions have been observed during
clinical trials. Administration of Cosentyx should be discontinued immediately and appropriate therapy initiated if an anaphylactic or other serious allergic reaction occurs. • Latex-sensitive individuals: The removable cap of the Cosentyx pre-filled syringes/pen contains a derivative of natural rubber latex. • Vaccinations: Cosentyx should not be given concurrently
with live vaccines. Pregnancy: Cosentyx should be used during pregnancy only if the benefits clearly outweigh the potential risks. Breast-feeding: Caution should be exercised when Cosentyx is administered to a woman who is breast-feeding. Adverse drug reactions: Very common (≥10%): Upper respiratory tract infections (nasopharyngitis, upper respiratory
tract infection, rhinitis, pharyngitis, sinusitis, tonsillitis). Common (1 to 10%): Oral herpes, diarrhea, urticaria, rhinorrhea. Uncommon (0.1 to 1%): Oral candidiasis, neutropenia, tinea pedis, conjunctivitis. Interactions: Live vaccines should not be given concurrently with Cosentyx. Packs and prices: Country-specific. Legal classification: Country-specific
1. Version 1.2 9-Dec 2015
The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
TABLE OF CONTENTS
Welcome Address by ACR President 4
Welcome Address by ESR President 5
Scientific Committee 6
Faculty List 7
About Dubai 8
ESR-ACR Speakers Profile 9
Program: Wednesday, September 19th 16
Program: Thursday, September 20th 17
Program: Friday, September 21st 18
RPS Speakers Profile 19
Program: Saturday, September 22nd 21
Acknowledgements 23
Profile of Sponsoring Companies 24
3
The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
Greetings attendees!
The American College of Rheumatology (ACR) is pleased to collaborate with the Emirates
Society for Rheumatology (ESR) by co-hosting the 4th Annual ESR Conference. This
conference marks a first-time partnership and brings together thought leaders from both
organizations to provide you with more than 30 presentations featuring emerging research
and noteworthy topics in the field of rheumatology.
Our partnership is designed to expand and share rheumatology knowledge on a global level
to benefit all involved and to ultimately improve care of our patients. In addition to participating in live sessions with
leading clinicians and researchers, attendees will receive a year-long complimentary subscription to ACR Beyond, a new
online streaming platform from the American College of Rheumatology. ACR Beyond offers access to a combination
of top-rated recorded educational sessions from past meetings as well as select live event streams from the ACR’s
upcoming annual meeting in Chicago this October.
We are aligned with the ESR’s mission of improving the standard and quality of rheumatologic care. Together, in support
of that mission, we have designed a compelling program which features the latest developments in clinical care and
research. We hope that the success of this event will allow us to continue to share resources that advance the study
and practice of rheumatology internationally.
Regardless of where you practice, ACR can help you save money and time, connect you with colleagues around the
world, and enhance your rheumatology knowledge and skills. Please be sure to visit the ACR Booth in the exhibit hall to
learn more about the ACR or ask our staff any questions.
Sincerely and with best regards,
David I. Daikh, MD, PhD
President, American College of Rheumatology
Professor of Medicine
Kenneth H. Fye Chair in Rheumatology Director, Rheumatology Fellowship Program
University of California, San Francisco
Chief, Rheumatology Section
San Francisco VA Medical Center
4
The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
Dear Colleagues and Friends,
On behalf of the Emirates Society for Rheumatology (ESR), and in partnership with the
American College for Rheumatology (ACR) it is our pleasure to invite you to the 4th Emirates
Society for Rheumatology Annual Conference which will be held between the 19th till the
21st of September 2018 at the Dubai Festival City.
This congress is aimed at creating a main platform for Rheumatology meetings in the
region, bridging rheumatologists in various specialties and aims at covering Rheumatoid Arthritis, SpondyloArthritis,
Vasculitis, Connective Tissue Diseases, Rare Diseases, Osteoporosis, Systemic lupus erythematous and much more.
We are more than confident that this scientific gathering will serve as an excellent networking platform with our fellow
colleagues to exchange professional experiences and insights with one another, as well as to explore possible forms of
international collaborations in research and education.
World renowned speakers from ACR and ESR will come together in this highly anticipated event and from this specialized
area to contribute in the literature of Rheumatology and present state-of-the art advances and updates in the field.
Attendees are expected from all over GCC and neighboring countries as well as from USA and Europe enriching the
congress with a multitude of diversities and backgrounds.
In closing, we aim at transforming the way we operate as Rheumatologists in the hope of continuously improving our
ability to perform and meet our daily challenges in our field. We not only want to offer you a unique opportunity but
would like to thank you for helping us shape the future in the field of Rheumatology.
Dr. Waleed AlShehhi
Consultant Rheumatologist
President of the Emirates Society for Rheumatology
5
The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
SCIENTIFIC COMMITTEE
Emirates Society For Rheumatology Planning & Executive Committee
Waleed AlShehhi President of the Emirates Society For Rheumatology
Atheer Alansari Vice President of the Emirates Society For Rheumatology
Imad Jassim President of the Scientific Committee
Bhavna Khan
Humeira Badsha
Ghita Harifi
Ahmed Abogamal
Gamal Ibrahim
American College of Rheumatology Planning Committee
David I. Daikh, MD, PhD President of the American College of Rheumatology
Paula Marchetta, MD, MBA ACR President-Elect
Sharad Lakhanpal, MBBS, MD Course Director, 2018 ESR-ACR Annual Conference ACR, Immediate Past President
American College of Rheumatology Executive Committee
David I. Daikh, MD, PhD President of the American College of Rheumatology
Paula Marchetta, MD, MBA ACR President-Elect
Charles M. King, II, MD ACR Treasurer
Ellen Gravallese, MD ACR Secretary
Abby G. Abelson, MD Foundation President
Sandra J. Mintz, MSN, RN ARHP President
6
The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
FACULTY LIST
Abdullah Hussaini Kenneth Saag
Abdurrahman Albaity Mawada Bahwairith
Alberto Cauli Mayadah Bawayan
Atheer Al-Ansari Michelle Petri
Ayman Esa Mohammed Attar
Basil Fathallah Mohammed Omair
Carol Langford Mohsin Malek
Christopher Ritchlin Mustafa El-Izzi
David Daikh Omar Hadid
David Walker Peter Nigrovic
Dinesh Khanna Raha Alturki
Faiza Aljishi Rajaie Namas
Fida Taha Rayan AlGhamdi
Ghita Harifi Reem Alqarra
Hadeel Albar Sami Bahlas
Hanan El Rayes Sharad Lakhanpal
Hani AlMoallim Suzan Attar
Hiba Azar Waleed AlShehhi
Huda Mehkri Waleed Hafiz
Ibrahim Almane Weam Alharbi
Imad Jassim Yasir Bawazeer
James R. O’Dell
7
The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
ABOUT DUBAI
Dubai is located on the Eastern coast of the Arabian Peninsula, in the south west corner of the Arabian Gulf. It is
extremely well known for its warm hospitality and rich cultural heritage, and the Emirati people are welcoming and
generous in their approach to visitors. With year-round sunshine, intriguing deserts, beautiful beaches, luxurious hotels
and shopping malls, fascinating heritage attractions and a thriving business community, Dubai receives millions of
leisure and business visitors each year from around the world.
Dubai Economy: The past few decades have witnessed incredible growth throughout all sectors of the Dubai economy.
The emirate’s government is constantly working to improve its commercial transparency and introduce dynamic
regulations that aid the formation of small and medium enterprises. Dubai’s economy is no longer reliant on oil, but is
more diversified, relying heavily on trade, services and finance sectors. With its central geographic location between
Asian and European markets, Dubai has worked hard to establish itself as an integral part of the global trade mechanism.
Its central location has also allowed Dubai to become a popular and accessible tourist destination.
8The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
ESR-ACR SPEAKERS PROFILE
Atheer Al Ansari
Dr. Atheer Al-Ansari is a Consultant rheumatologist trained and worked in UK for 18 years and just moved to
Abu Dhabi. Originally he graduated from Baghdad University and trained in UK, he is holding the CCST degree
in rheumatology and FRCP Glasgow / London and MRCP Ireland. He was a consultant Rheumatologist at
Robert Jones and Agnes Hunt tertiary center and principal investigator at their research unit. He moved
to Abu Dhabi 3 years ago as consultant rheumatologist at Mediclinic Middle EAST International Hospitals.
Moreover, he is Board member the head of scientific committee at Emirates Society for Rheumatology (ESR),
member of Emirates Society for Osteoporosis (EOS) and co-Chair Scientific Committee for the 19th Asian
and Pacific League Against Rheumatism (APLAR) in Dubai 2017. Dr. Al-Ansari has numerous publications and
presentations promoting the best practice of Rheumatology
Waleed AlShehhi
President of the Emirates Society For Rheumatology
• Dr. Waleed AlShehhi is a Consultant Rheumatologist at Dr. Sulaiman Al Habib Hospital, Dubai Health Care City
• Chairman for the Asia Pacific league against Rheumatism 2017 in Dubai
• Dr. AlShehhi obtained his medical degree and Rheumatology specialty from the Royal College of Surgeons
and Physicians, respectively, from Ireland.
• Dr. AlShehhi is a certified EULAR MSK-US Teacher, examiner for the Royal college of physicians Ireland,
Fellow for the RCPI, fellow of the ACR
Hiba Azar
Dr Hiba AZAR graduated from the Saint Joseph University, Faculty of medicine, Beirut, in 2003 and obtained
her diploma in Nephrology and Arterial Hypertension in 2008. She has a Master’s degree of Immunology
from Descartes, Paris 5 University. After an experience of a few years in Paris, she returned back home and
is actually practicing in the Nephrology Department at Hotel Dieu de France University Hospital, Beirut. She
is also Clinical Instructor in Saint Joseph University. Dr AZAR has a special interest in kidney transplantation
and in glomerular diseases and works in collaboration with her rheumatology colleagues treating patients
with systemic diseases.
David Daikh
President of the American College of Rheumatology.
Dr. David Daikh is the Rheumatology Division Chief at the SFVA Medical Center, and director of the rheumatology
fellowship program at UCSF. Dr. Daikh’s research focuses on immune mechanisms of rheumatic disease,
and he directs a core laboratory that serves a number of investigators at UCSF.
9The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
ESR-ACR SPEAKERS PROFILE
Hanan Al Rayes
President of the Saudi Society for Rheumatology
Consultant Rheumatologist, Deputy Director Medicine Department Prince Sultan Military Medical City
Chairperson of evidence based medicine committee (PSMMC)
Board member of Saudi Osteoporosis Society
Member in Medical job Recruitment committee of all Saudi Military Hospital
Deputy Director Medical Studies (PSMMC)
Chairperson of P&T Committee
Chairperson of Medicine Quality Management
Mustafa El-Izzi
Senior Consultant Rheumatologist at Mediclinic Welcare Hospital, Mediclinic City Hospital and Mediclinic
Dubai Mall, Dubai, United Arab Emirates since October 2011
Member of the Royal College of Physicians (MRCP-UK) since 1982
Fellow of the Royal College of Physicians of Edinburgh FRCP (Edin) since 2000
Current Vice President of the Emirates Osteoporosis Society (EOS)
Basil Fathallah
Dr. Basil Fathalla, is a pediatric rheumatology consultant at Al Jalila Children’s Specialty Hospital in Dubai
since January 2016. Dr. Fathalla completed his medical school at the School of Medicine – Damascus
University, Syria during 1989 – 1996 and Pediatric Residency training at Henry Ford Hospital in Detroit, USA
during1997 – 2000. Dr. Fathalla then completed pediatric rheumatology training at the Floating Hospital
for Children / The New England Medical Center / Tufts University in Boston USA during 2000 - 2003.
Dr. Fathalla is American Board Certified in Pediatrics and Pediatric Rheumatology and gained his experience
through academic positions in various tertiary care hospitals including St. Christopher’s Hospital for Children
in Philadelphia, Children’s Hospital of Michigan in Detroit, and Hamad General Hospital in Qatar.
Omar Hadid
Omar Hadid is a consultant ophthalmologygist at Tawam Hospital. He has dual qualifications after undertaking
training both in general medicine and ophthalmology. He has a special interest in inflammatory eye disease
and has had special training in the world-renowned medical eye unit at St Thomas' Hospital in London.
He also has specialised training in Oculoplastics and Orbital diseases. He has worked as a consultant in the
NHS in the UK for over 6 years. He also has an interest in training and reaesch and is an honorary Clinical
Lecturer in the University of Sheffield
10The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
ESR-ACR SPEAKERS PROFILE
Ghita Harifi
Dr. Ghita Harifi, Rheumatologist, has been practicing in Dubai since 2012. Prior to joining Dr Humeira Badsha
Medical Center (HBMC), she was at Dubai Hospital where set up and ran the Musculoskeletal Ultrasound
Clinic as well as the General Rheumatology and Early Arthritis clinics.
Dr. Harifi is a Fellow of the Université de Strasbourg, one of France’s best research universities specialized in
auto-immune diseases. She also completed her Post-Graduate Certificate in Interventional Rheumatology,
and her French Certificate in Musculoskeletal Ultrasound from L'Université Pierre et Marie Curie (UPMC),
Sorbonne Universités.
Dr. Harifi is an expert in Musculoskeletal Ultrasound and she has been leading many teaching programs in
this field in the UAE.
She is actively involved in research and education, and has been published in numerous peer reviewed
journals.''
Imad Jassim
• Graduated Baghdad University with MBChB in Medicine and Surgery
• Certified Diploma in Internal Medicine University of London, Imperial college 1995 with distinction
• Completed medical training in UK achieving MRCP London 1999
• Completed MSc in clinical rheumatology from Manchester university 2006
• Achieved CCT in rheumatology from Royal College of London 2007
• Consultant Rheumatologist in England from 2005 -now
• Last job was in East Kent University Hospital NHS Trust from 2011-2014
• Moved to UAE 2014 Currently Consultant Rheumatologist and Head of department
• Head of the Scientific committee of ESR
• Member of British society of rheumatology
Dinesh Khanna
MD, MSc
University of Michigan, Ann Arbor, MI
Dinesh Khanna, MD, MSc, is an Professor of Medicine and Director, University of Michigan Scleroderma
Program. Dr. Khanna has published over 300 peer-reviewed articles and book chapters. His current research
focus on developing, validating, and refining outcome measures in rheumatic diseases and designing novel
trials. He was awarded the 2015 Henry Kunkel Young Investigator Award from the American College of
Rheumatology.
11The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
ESR-ACR SPEAKERS PROFILE
Sharad Lakhanpal
Immediate Past President, American College of Rheumatology
Rheumatology Associates, Dallas, TX
Dr. Sharad Lakhanpal is a practicing rheumatologist in Dallas, TX, USA. He is Clinical Professor of Internal
Medicine at UT Southwestern Medical Center in Dallas, TX. He is also an investigator at Metroplex Clinical
Research Center in Dallas. He did rheumatology fellowship at Mayo Clinic and received several awards during
his training. He has been listed in the Best Doctors in America since 1996. He has over 100 publications.
He is a Fellow of the American College of Rheumatology and the American College of Physicians.
Carol Langford
MD, MHS
Cleveland Clinic, Cleveland, OH
Carol A. Langford, MD, MHS is the Director of the Center for Vasculitis Care and Research within the Department
of Rheumatic and Immunologic Diseases. She is an Associate Professor of Medicine of the Cleveland Clinic
Lerner College of Medicine of Case Western Reserve University and became Vice-Chair of Rheumatology for
Research in 2007. In 2011, she was named the Harold C Schott endowed Chair in Rheumatic and Immunologic
Diseases.
Mohsin Malek
FRCP UK - Consultant Dermatologist
Dr Mohsin Malik is an established and highly skilled physician with over 20 years of experience in dermatology.
He completed his specialist dermatology training in Republic of Ireland before moving to UK where he worked
as Consultant Dermatologist at Royal London Hospital and Chief of Dermatology at Broomfield Hospital.
He was also Honorary Senior Lecturer at Barts and The London. He is now in UAE since 2014 working at
Tawam Hospital affiliated with Johns Hopkins as a Senior Dermatologist. Dr Malik is Fellow of Royal College
of Physicians UK, and member of Royal Society of Medicine UK, and Emirates Dermatology Society, and has
a number of publications and presentations at international meetings to his credit. Dr Malik deals with both
adult and pediatric dermatology with special interest in eczema, cutaneous allergy, acne, psoriasis and skin cancer.
Rajaie Namas
MBBCh . Dr Namas is a Staff Physician in the Medical Subspecialties Institute at Cleveland Clinic Abu Dhabi.
Prior to joining Cleveland Clinic Abu Dhabi, Dr. Namas served at the University of Michigan as a Clinical Lecturer
for two years, and was supported by the National Institute of Arthritis, Musculoskeletal and Skin Diseases.
He was then promoted to Clinical Assistant Professor at the University of Michigan. Dr. Namas received his
medical degree from the University of Tripoli, Libya. He completed his postdoctoral training at the University
of Pittsburgh, Pennsylvania, US, followed by his residency in Internal Medicine at Hurly Medical Center/
Michigan State University in Flint, Michigan, US. Dr. Namas completed his clinical and research fellowship
in Rheumatology at the Wayne State University/Henry Ford Hospital in Detroit, Michigan, US. Dr. Namas is
currently active in numerous research projects focused on treatment strategies, measures of outcome, and
translational studies of potential laboratory markers of disease activity. He has multiple publications and
awards in the field of Rheumatology, and is a reviewer on multiple peer-reviewed journals. Dr. Namas is a
member and fellow of the American College of Rheumatology and American College of Physicians.
12The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
ESR-ACR SPEAKERS PROFILE
Peter Nigrovic
MD
Brigham and Women's Hospital, Boston, MA
Dr. Peter Nigrovic is Associate Professor of Medicine at Harvard Medical School and an adult and pediatric
rheumatologist at Boston Children’s Hospital and the Brigham and Women’s Hospital. His laboratory studies
basic mechanisms of inflammation, with a focus on autoimmune arthritis. He leads the Center for Adults
with Pediatric Rheumatic Illness (CAPRI), a clinical program dedicated to the care of adults with childhood-
onset rheumatic illness. He directs translational research for the Childhood Arthritis and Rheumatology
Research Alliance (CARRA) and is co-editor of Arthritis & Rheumatology.
James R. O’Dell
MD - Past President, American College of Rheumatology - University of Nebraska Medical Center, Omaha, NE
James R. O’Dell, MD is the Stokes Schackleford Professor of Internal Medicine, Vice-Chairman of Internal
Medicine and Chief of Rheumatology at the University of Nebraska Medical Center and the Omaha VA. He
also has served as Director of the Internal Medicine Residency Training Program at UNMC for the last 25.Dr.
O’Dell founded and has directed the Rheumatoid Arthritis Investigational Network (RAIN) for the last 22
years. Dr. O’Dell is the PI of the large multinational RA research comparative effectiveness study based at
the VA. Dr. O’Dell has published extensively, mostly in the area of RA. He is the co-editor of the “Textbook of
Rheumatology” and editor of “Kelley’s Textbook of Medicine”.
Mohammed Omair
Dr. Mohammed Omair is an associate professor and rheumatologist at King Saud University.
His area of interest includes systemic sclerosis and rheumatoid arthritis.
He is the founding president of the Charitable Association for Rheumatic diseases
Michelle Petri
MD - Johns Hopkins University School of Medicine, Baltimore
Michelle Petri is a Professor of Medicine in the Division of Rheumatology and Director of the Lupus Center
at the Johns Hopkins University School of Medicine and Johns Hopkins.Professor Petri’s research focuses on
several aspects of systemic lupus erythematosus (SLE), including atherosclerosis, antiphospholipid syndrome
(APS), lupus nephritis, and pregnancy. The Hopkins Lupus Cohort, started by Professor Petri in 1987, is a
longitudinal study of the incidence and pathogenesis of thrombotic events and coronary artery disease in SLE
and serves as a useful resource for other SLE-related research. The Hopkins Lupus Pregnancy Center, of which
Professor Petri is a Co-Director, has a database of over 400 pregnant patients, providing information on lupus
activity, antiphospholipid tests, and pregnancy outcomes. Professor Petri has authored over 400
papers and chapters on SLE and APS.
13The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
ESR-ACR SPEAKERS PROFILE
Christopher Ritchlin
MD, MPH - University of Rochester, Rochester, NY
Christopher Ritchlin, MD, MPH is a Professor of Medicine and Division Chief of the Allergy, Immunology
& Rheumatology Division at University of Rochester Medical Center in Rochester, New York.
Dr. Ritchlin's laboratory is engaged in translational research that is centered on mechanisms of bone resorption
in psoriatic arthritis and axial spondylarthritis and on the role of the lymphatic system in joint flares observed
in rheumatoid and psoriatic arthritis.
Kenneth Saag
MD, MS - University of Alabama Birmingham, Birmingham,
AL Kenneth Kenneth Saag, MD, MSc, is the Jane Knight Lowe Professor of Medicine, Division of Clinical
Immunology and Rheumatology, at the University of Alabama at Birmingham. He is Vice-Chair for the UAB
Department of Medicine and Director of the Center for Outcomes Research (COERE). He’s published over 300
peer-reviewed manuscripts; authored over 100 reviews, editorials, and book chapters. He recently published
the second edition of the “Diagnosis and Management of Osteoporosis” Dr. Saag is a past board member of
the ACR, and co-developer of the 2008 and 2011 ACR Recommendations on the Treatment of Rheumatoid
Arthritis. He is the Past President of the National Osteoporosis Foundation.
David Walker
Dr. David Walker B.A., M.B.B.S., M.A.,M.R.C.P., M.D., F.R.C.P. has been a Consultant Rheumatologist since
1987 having completed medical training at Canterbury and Newcastle. Dr. Walker has always had a
busy clinical caseload but has retained throughout his career a keen research interest centred upon the
immunogenetics of rheumatic diseases. Dr. Walker performed a large family study of rheumatoid arthritis
and further studies have developed from this unique population. Dr. Walker’s other main academic interest
is in quantifying outcomes. This started with trying to measure the severity of disease for genetic studies,
but has now developed beyond this. Having looked at the successes of aggressive treatment (i.e. patients
with multiple joint replacement) and the failures (i.e. those languishing on the Social Service waiting lists
being chairbound) he is still pursuing other studies in this area. Since 1994 Dr. Walker has regularly done
commercial research as a principal investigator Dr. Walker has always had extensive teaching, mentoring
and examining commitments in Newcastle and surrounding environs as academic supervisor for registrars,
M.D’s, PhD’s and also regularly undertakes teaching of ancillary professions which is a central tenant of the
musculoskeletal unit. Dr. Walker has sat on various editorial boards over the years for Journals including
British Journal of Rheumatology & Clinical Rheumatology and has been involved as an advisor to NICE in
regulatory submissions. Dr. Walker is widely published in Rheumatology and speaks regularly at congresses
around the world.
14The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
15The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
Wednesday 19th September 2018
08:00 - 08:30 Welcome Note by the President of the Emirates Society for Waleed AlShehhi
Rheumatology
08:30 - 10:00 Session I Chair: Waleed AlShehhi
08:30 - 09:15 Ophthalmology For Rheumatologists Omar Hadid
09:15 - 10:00 Nephrology For Rheumatologists Hiba Azar
10:00 - 10:15 Coffee Break Sponsored by Pfizer
10:15 - 11:45 Session II Chair: Abullatif Al-Arfaj
10:15 - 11:00 Dermatological Manifestations of Rheumatologic Diseases Mohsin Malek
11:00 - 11:45 Pulmonary Arterial Hypertension in Connective Tissue Disease Mohammed Omair
the Role of the Rheumatologist
11:45 - 12:30 Symposium Sponsored by Pfizer Chair: Atheer Al-Ansari
Latest Updates in JAK Inhibitors Waleed AlShehhi
12:30 - 13:30 Lunch Break
13:30 - 15:00 Session III: Special Interest - Group Session Chair: Mohamed Omair
13:30 - 14:00 Management of RA / IA Practical Ways to Improve Services Imad Jassim
14:00 - 14:30 Atypical Osteoporosis Mustafa El-Izzi
14:30 - 15:00 Disease Characteristic of Scleroderma in a Single Center Rajaie Namas
Cohort in UAE
15:00 - 15:45 Symposium Sponsored by Novartis
IL-17A Inhibition in Spondyloarthritis: Long Term Implications Atheer Al Ansari
for Clinical Practice Imad Jassim
15:45 - 16:00 Coffee Break Sponsored by Novartis
16:00 - 17:30 Session IV: Special Interest - Group Session Chair: Imad Jassim
16:00 - 16:30 PsA New Insights Waleed AlShehhi
16:30 - 17:00 Systemic Onset Juvenile Idiopathic Arthritis: Basil Fathallah
Past, Present and Future
17:00 - 17:30 Inflammatory Serositis Atheer Al-Ansari
16The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
Thursday 20th September 2018
08:00 - 08:30 Welcome Note By the American College of Rheumatology David Daikh
Sharad Lakhanpal
08:30 - 10:00 Session V Co-Chairs: Sharad Lakhanpal - Waleed AlShehhi
08:30 - 09:15 Update On Clinical Aspects And Treatment Of ANCA Associated Vasculitis Carol Langford
09:15 - 10:00 Non-Radiographic Spondyloarthritis From Diagnosis To Management Christopher Ritchlin
10:00 - 10:15 Coffee Break Sponsored by Pfizer
10:15 - 11:45 Session VI Co-Chairs: Sharad Lakhanpal - Bhavna Khan
10:15 - 11:00 New Classification Criteria For SLE David Daikh
11:00 - 11:45 Evidence-Based Treatment of Lupus Nephritis Michelle Petri
11:45 - 12:30 Symposium Sponsored by Pfizer Chair: Humeira Badsha
Raising the Bar in PSA Treatment Ghita Harifi
12:30 - 13:30 Lunch Break
13:30 - 15:00 Session VII Co-Chairs: Sharad Lakhanpal - Ghita Harifi
13:30 - 14:15 Management Of Scleroderma Dinesh Khanna
14:15 - 15:00 Update On Clinical Aspects And Treatment Of Large Vessel Carol Langford
Vasculitis
15:00 - 15:45 Symposium Sponsored by Lilly Chair: Bhavna Khan
Challenging the Rheumatoid Arthritis Treatment Standards with David Walker
JAK Inhibitors: Can we Change the Paradigm?
15:45 - 16:00 Coffee Break Sponsored by Lilly
16:00 - 17:30 Session VIII Co-Chairs: Sharad Lakhanpal - Mustafa Al Izzi
16:00 - 16:45 Difficult to Treat Rheumatoid Arthritis James R. O’Dell
16:45 - 17:30 Osteoporosis 2018: Bones of Contention Kenneth Saag
17:30 - 18:15 Symposium Sponsored by Lilly Chair: Humeira Badsha
Ixekizumab in the Management of Psoriatic Arthritis Alberto Cauli
19:00 - 21:00 Pfizer Workshop Chair: Waleed AlShehhi
New Horizons in PSA Management Christopher Ritchlin
Waleed AlShehhi
17The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
Friday 21st September 2018
08:30 - 10:00 Session IX Co-Chairs: Sharad Lakhanpal - Rajaie Namas
08:30 - 09:15 Auto Inflammatory Conditions Diagnosis and Management Peter Nigrovic
09:15 - 10:00 Scleroderma-Associated ILD and PAH Dinesh Khanna
10:00 - 10:15 Coffee Break Sponsored by Pfizer
10:15 - 11:45 Session X Co-Chairs: Sharad Lakhanpal - Humeira Badsha
10:15 - 11:00 Evidence-Based Management of Early Rheumatoid Arthritis James R. O’Dell
11:00 - 11:45 Gout and Hyperuricemia: Comorbidities and Complexities with Therapies Kenneth Saag
11:45 - 13:00 Prayer Followed By Lunch
13:00 - 13:45 Symposium Sponsored by GSK
SLE: where do we Stand Now? Hanan Al Rayes
13:45 - 15:15 Session XI Co-Chairs: Sharad Lakhanpal - Gamal Ibrahim
13:45 - 14:30 Optimal Management of Psoriatic Arthritis Christopher Ritchlin
14:30 - 15:15 Systemic JIA and Adult Onset Still’s Disease Peter Nigrovic
15:15 - 15:30 Coffee Break Sponsored by Novartis
15:30 - 17:00 Session XII Co-Chairs: Sharad Lakhanpal - Ahmed Abogamal
15:30 - 16:15 Biomarkers for SLE and Connective Tissue Diseases David Daikh
Now and in the Future
16:15 - 17:00 Anti-phospholipid Antibodies, APLS and Management of the Michelle Petri
Hypercoaguable Patient
17:00 Closing Ceremony
18The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
RPS SPEAKERS PROFILE
Abdurrahman Albaity
Consultant Internist, Rheumatology Fellow, King Faisal Specialist Hospital and Research Center, Jeddah,
Saudi Arabia
Faiza Aljishi
Consultant Internist and Rheumatologist, Chairwoman, Department of Medicine; Section Head, Division of
Rheumatology; King Fahd Specialist Hospital, Dammam, Saudi Arabia.
Hani AlMoallim
Canadian and American boards in Internal Medicine and Rheumatology, Professor of Medicine, Vice-
dean, Medical College, Umm Al-Qura University, Makkah, Saudi Arabia. Consultant Rheumatologist and
Educationalist with Medical Education diploma from University of Dundee. Supervisor, Alzaidi Chair of
Research in Rheumatic Diseases
Mohammed Attar
Consultant Internist and Rheumatologist, Armed Forces Hospital, Alhada, Saudi Arabia. Subspecialized in
systemic lupus erythematosus.
Suzan Attar
Professor of Medicine and Rheumatology, Medical College, King Abdulaziz University, Jeddah, Saudi Arabia.
Consultant Rheumatologist, King Abdulaziz University hospital, Jeddah, Saudi Arabia.
19The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
RPS SPEAKERS PROFILE
Sami Bahlas
Professor of Medicine and Rheumatology, Medical College, King Abdulaziz University, Jeddah, Saudi Arabia.
Consultant Rheumatologist, King Abdulaziz University hospital, Jeddah.
Mayadah Bawayan
Consultant Internist and Rheumatologist, East Jeddah Hospital, Jeddah, Saudi Arabia.
Yasir Bawazeer
Assistant Professor of Medicine and Rheumatology, Medical College, King Abdulaziz University, Jeddah,
Saudi Arabia. Consultant Rheumatologist, King Abdulaziz University hospital, Jeddah.
Waleed Hafiz
Assistant Professor of Medicine and Rheumatology, Medical College, Umm Al-Qura University, Makkah,
Saudi Arabia. Consultant Rheumatologist, Alnoor Specialist Hospital, Makkah, Saudi Arabia. Scientific
Coordinator, Alzaidi Chair of Research in Rheumatic Diseases.
20The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
SATURDAY 22ND SEPTEMBER 2018
Rheumatology Practice Symposium (RPS)
In collaboration with Alzaidi Chair of Research in Rheumatic Diseases
Umm Alqura University Makkah, Saudi Arabia
08:00 - 08:15 Welcoming and Highlights of the Program Hani AlMoallim
08:15 - 09:45 Basics in Rheumatology
08:15 - 08:45 Approach to Arthritis Hani AlMoallim
08:45 - 09:15 Laboratory Interpretation in Rheumatic Diseases Abdurrahman Albaity
09:15 - 09:45 Pharmacotherapy in Rheumatology Waleed Hafiz
09:45 - 10:00 Coffee Break
10:00 - 12:20 MSK Examination Workshops
10:00 - 10:15 General Introduction and Principles of MSK Examination Hani AlMoallim
10:15 - 12:20 Workshops Instructors Supervisors
10:15 - 10:40 Hands Mawada Bahwairith & Weam Alharbi Sami Bahlas
10:40 - 11:05 Shoulders Raha Alturki & Reem Alqarra Yasir Bawazeer
11:05 - 11:30 Knee Ayman Esa & Abdullah Hussaini Mohammed Attar
11:30 - 11:55 Hips Rayan AlGhamdi & Ibrahim Almane Faiza Aljishi
11:55 - 12:20 Back Hadeel Albar, Huda Mehkri & Fida Taha Suzan Attar
12:20 - 13:00 Prayer & Lunch
13:00 - 14:45 Comprehensive Examination of Common Rheumatic Diseases and Presentations
13:00 - 13:45 General Introduction and Principles of Comprehensive Exam Waleed Hafiz
13:45 - 14:45 Rotating Workshops
13:45 - 14:00 Patients with Suspected Mononeuritis Multiplex Yasir Bawazeer
14:00 - 14:15 Patients with Early Arthritis (RA and/or SLE) Abdurrahman Albaiti
14:15 - 14:30 Patients with Suspected Vasculitis and/or Myopathy Mayadah Bawayan
14:30 - 14:45 Patients with Suspected Scleroderma Waleed Hafiz
14:45 - 15:00 Coffee Break
15:00 - 16:45 Management of Common Rheumatological Diseases: Case-Based Discussions and Reviews
15:00 - 15:20 Rheumatoid Arthritis Hani Almoallim
15:20 - 15:40 Pregnancy and Rheumatic Disease Faiza Aljishi
15:40 - 16:00 Crystal Induced Arthritis Sami Bahlas
16:00 - 16:20 Spondyloarthritis Suzan Attar
16:20 - 16:40 Systemic Lupus Erythematosus Mohammed Attar
16:40 - 16:45 Closing Remarks and Certificates
21● Could it be time to consider adding BENLYSTA
instead of more of the same?
● Adding BENLYSTA provided significant benefits
vs. standard therapy alone in patients with
persistent disease activity.1,2,*,†
● Superior reductions in SLE disease activity.2,‡
● A 39% relative risk reduction of severe flare.2,§
● A reduction in corticosteroid dose in patients on ≥7.5 mg/day at baseline.2,¶
● An improvement in fatigue scores as early as Week 8.2,¥
● Similar adverse event profile to standard therapy alone.1
1. Benlyta Local Prescribing Information. 2. van Vollenhoven RF et al. Ann Rheum Dis. 2012; 71: 1343-1349. *Defined by low complement and positive
anti-dsDNA at baseline. †BLISS-52 and BLISS-76 pooled data. ‡51.5% SRI response rate vs. 31.7% with standard therapy + placebo (pThe 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
ACKNOWLEDGEMENTS
We wish to thank the following companies who, through their generosity
have helped make this Congress possible
Diamond
Platinum
Gold
Contributors
Associations
LEBANON UAE
|
Organized by: 4th Floor, Qubic Center DMCC Business Centre
Daoud Ammoun Street Almas Tower
Horsh Tabet - Sin El Fil Jumeirah Lakes
Official Congress Organizers P.O. Box: 90-361 Beirut
Tel: +961 1 510880/1/2/3
Dubai, United Arab Emirates
Unit No: 3820
Mobile: +961 71 103123 Mobile: +971 50 9110475
23The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
PROFILE OF SPONSORING COMPANIES
Pfizer Lilly
At Pfizer, we apply science and our global resources to bring Lilly is a global healthcare leader that unites caring with
therapies to people that extend and significantly improve discovery to make life better for people around the world. We
their lives. We strive to set the standard for quality, safety were founded more than a century ago by a man committed
and value in the discovery, development and manufacture of
to creating high-quality medicines that meet real needs, and
health care products. Our global portfolio includes medicines
and vaccines as well as many of the world’s best-known today we remain true to that mission in all our work. Across
consumer health care products. the globe, Lilly employees work to discover and bring life-
Every day, Pfizer colleagues work across developed and changing medicines to those who need them, improve the
emerging markets to advance wellness, prevention, understanding and management of disease, and give back to
treatments and cures that challenge the most feared
communities through philanthropy and volunteerism
diseases of our time.
Consistent with our responsibility as one of the world’s
premier innovative biopharmaceutical companies, we
collaborate with health care providers, governments and
local communities to support and expand access to reliable, GlaxoSmithKline
affordable health care around the world. For more than 150
years, Pfizer has worked to make a difference for all who rely
on us.
At Pfizer, we’re committed to creating an environment where
our colleagues can achieve success while contributing to
the improved health of the world. We walk in as scientists,
managers, manufacturers, senior executives and recent
One of the world’s leading research-based pharmaceutical
graduates. No matter where we come from or where we take
our careers, we share a common purpose to make the world and healthcare companies – is committed to improving
a healthier place. the quality of human life by enabling people to do more,
feel better and live longer. With a proven track record for
providing medicines, vaccines and consumer products, the
company has a long-standing innovation history of over 300
Novartis
years and its presence in the Gulf Cooperation Council (GCC)
has been expanding for the last 65 years – providing greater
access and innovation to people in the region ever since. For
further information please visit www.gsk.com
Novartis provides innovative healthcare solutions that address
the evolving needs of patients and societies. Headquartered
in Basel, Switzerland, Novartis offers a diversified portfolio
to best meet these needs: innovative medicines, eye care
and cost-saving generic pharmaceuticals. Novartis is the
only global company with leading positions in these areas.
Novartis Group companies employ approximately 118,000
full-time-equivalent associates. Novartis products are sold
in approximately 155 countries around the world.
www.novartis.com
24The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
PROFILE OF SPONSORING COMPANIES
Abbvie Emirates Society For Rheumatology
Abbvie may have been founded in 2013, but our roots run The Emirates Society for Rheumatology ESR was founded
deep. In 2013, we became a separate company from Abbott, in 2008 and the current president is Dr. Waleed AlShehhi,
though we share a common legacy and strong prospects for who is a Consultant Rheumatologist at Dr. Sulaiman AlHabib
Medical Centre and hospital, Dubai Health Care City. His term
future success. of presidency runs from January 2016 to January 2019.
Our name represents our connection to the past and the
future. When we became our own company, AbbVie formed The society aims to increase awareness and standard of
a new kind of enterprise - a biopharmaceutical company. We health professionals to have arthritis and musculoskeletal
conditions diagnosed early, treated effectively and prevented
blend the stability, global scale, resources and commercial
where ever possible in the hope that early and correct
capabilities of a pharmaceutical company with the focus and diagnosis will lead to improve patient’s well being and a
culture of a biotech. prosperous future.
Today, our ~29,000 employees around the world focus on
delivering transformational medicines and therapies that ESR is committed in supporting health care providers in
their work by providing them with high-quality professional
offer significant patient benefits.
orientations and guidance. Collaboration with other medical
and surgical specialties is at the heart of their core values.
American College of Rheumatology Saudi Society for Rheumatology
ﺱﺳﻌﺩﻏﺋ ﻓﻄﺭﺍ
ﺽ ﺍﻝ ﺋ ﺍﻝ
ﺭﻭ
ﻄﺍﺕ
ﺳﻐ
ﺔﻡ
ﻐﺞﻡ
ﺍﻝ
SAU
GY
S
LO
S
DI
.
. R
TO
O A
S
CI
ET UM
Y FOR RHE
The American College of Rheumatology is an international
Vision
medical society representing over 9,600 rheumatologists
SSR aims to be a leading organization in the field of
and rheumatology health professionals with a mission Rheumatology with significant positive impact on patient
to empower rheumatology professionals to excel in their care in Saudi Arabia.
specialty. In doing so, the ACR offers education, research,
advocacy and practice management support to help its Mission
members continue their innovative work and provide quality To Support our members to deliver the best care and advance
the science of rheumatology which will impact on children
patient care.
and adult’s lives with rheumatic and musculoskeletal
diseases in Saudi Arabia.
25The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
PROFILE OF SPONSORING COMPANIES
Pakistan Society for Rheumatology Official Congress Organizers: Infomed
Infomed International for Events was established in 1993
Pakistan Society for Rheumatology is a pioneering platform and is one of the region’s leading event management
which was formed in 1995, with a view to enhance the companies. The key strengths of Infomed have remained
knowledge about rheumatic diseases in Pakistan and to constant, delivering events that are innovative, interesting,
encourage further development of expertise in this field. memorable and enabling every client to consistently achieve
It was in the early 1990’s that a small group of and surpass their event goals.
Rheumatologists who had trained in the UK and USA returned Their reputation and longstanding loyalty of their clients are
to Pakistan with the commitment to introduce advanced both clear testimonies to the quality of their work.
Rheumatology education and care. With the blessing of the Well known within the pharmaceutical and medical industries
old guard, the flame was passed on to the new generation as a leading medicinal events management company,
and since then there has been no looking back. Infomed is also proud to be accredited by the International
The first set of office bearers included Dr. Azra Ali (President), Association of Professional Congress Organizers (IAPCO).
Dr. Khurram Manzoor Chowdhry (President-elect), Dr. Abid For more Information, Kindly visit: www.infomedweb.com
Farooqi (General Secretary), Dr Kamran Hameed (Joint
Secretary) and Dr. Shahid Abbas (Finance Secretary). The first
set of office bearers succeeded in getting the credentials of
the Society accepted internationally within a few months
by Asia Pacific league of associations for Rheumatology
(APLAR).
Within this short span of time a number of international
publications of original scientific research have appeared
in leading rheumatology journals and Pakistan’s name is
beginning to be credible in the world of Rheumatology today.
Zaidi Chair of Research in Rheumatic Diseases
Vision
To make Umm Al-Qura university the leader in carrying out,
supervising and participating in the doing researches in the
field of rheumatic diseases in Saudi Arabia
Mission
Provide an appropriate scientific atmosphere to do scientific
researches in the field of rheumatic diseases,and to give
technical support to researchers and scientists. Also,
participate in international scientific research in rheumatic
diseases.
26The 4th Annual Conference of the Emirates Society For Rheumatology
in partnership with the American College of Rheumatology
19 - 22 September 2018 | Dubai Festival City - Convention Center
27You can also read
